Comparison of Aripiprazole and Other Atypical Antipsychotics for Pediatric Bipolar Disorder: A Retrospective Chart Review of Efficacy and Tolerability.
- Author:
Jooyoung OH
1
;
Jhin Goo CHANG
;
Seul Bi LEE
;
Dong Ho SONG
;
Keun Ah CHEON
Author Information
1. Division of Child and Adolescent Psychiatry, Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea. kacheon@yuhs.ac
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Bipolar disorder;
Child psychiatry;
Antipsychotic agents;
Aripiprazole
- MeSH:
Adolescent;
Aged;
Antipsychotic Agents;
Bipolar Disorder;
Child;
Child Psychiatry;
Dibenzothiazepines;
Female;
Humans;
Isoxazoles;
Male;
Medical Records;
Piperazines;
Pyrimidines;
Quinolones;
Retrospective Studies;
Risperidone;
Weights and Measures;
Aripiprazole;
Quetiapine Fumarate
- From:Clinical Psychopharmacology and Neuroscience
2013;11(2):72-79
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: This study compared the efficacy and tolerability of aripiprazole with that of other atypical antipsychotics by examining patients with pediatric bipolar disorder (PBD) at a child and adolescent psychiatric clinic in a university hospital in Korea. METHODS: We reviewed the medical records of 127 pediatric patients with bipolar disorder aged 4-18 years treated at Department of Child and Adolescent Psychiatric, Yonsei University Severance Hospital between January 2010 and October 2011 to collect demographic and clinical data. Using the Clinical Global Impression (CGI) scales, we evaluated levels of severity of and improvements in symptoms at the first, second, third, fourth, and fifth hospital visits. RESULTS: The mean age of patients was 12.29+/-3.47 years. The sample included 91 (71.7%) male and 36 (28.3%) female patients. Aripiprazole was prescribed to 62 (48.8%) patients, risperidone to 52 (40.9%), quetiapine to 11 (8.7%), and paliperidone to two (1.6%). Patients treated with aripiprazole had lower CGI-Severity (CGI-S) scores than did patients treated with other atypical antipsychotics at the second and third visits. The CGI-Improvement (CGI-I) scores of patients treated with aripiprazole were lower at the second visit. Treatment with atypical antipsychotics was well tolerated, and no serious or fatal side effects were observed. CONCLUSION: The present retrospective chart review suggests that atypical antipsychotics may be effective and safe for the treatment of patients with PBD. In particular, treatment with aripiprazole may be more effective than treatment with other atypical antipsychotics in the early phase. These results should be verified in future multi-center controlled studies.
